



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/824,527	04/15/2004	Bum-Joon Kim	5823.0260-00	7151

22852 7590 04/16/2008
FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
LLP
901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413

EXAMINER

SITTON, JEHANNE SOUAYA

ART UNIT	PAPER NUMBER
----------	--------------

1634

MAIL DATE	DELIVERY MODE
-----------	---------------

04/16/2008

PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Continuation of Substance of Interview including description of the general nature of what was discussed: The examiner indicated that the method claims would be rejoined and suggested using the traditional Markush recitation "selected from the group consisting of" in claims 6, 7, 8. Additionally, the examiner indicated that a number of SEQ ID NOS were identical to each other. They are: 43 and 45; 46 and 34; 47 and 48; and 51-54. The examiner indicated that one of each of the duplicate SEQ ID NOS should be deleted from the claims. It was acknowledged that the duplication arose from the different strains which were isolated and sequenced and indicated in the sequence listing. However, the examiner pointed out that the SEQ ID NO was only a representation of a particular nucleotide sequence, not to other information in the sequence listing, and that deletion of duplicative SEQ ID NOS did not alter the scope of the claims. Applicant's attorney agreed to the changes in the attached Examiner's amendment.